Phase 2 RCT in 120 men with metastatic castration-resistant prostate cancer and bone metastases: olaparib plus radium-223 improved median radiographic PFS vs radium-223 alone (8.9 v 4.7 months; HR 0.50). Grade ≥3 treatment-related AEs 56% v 33%; median OS similar.
RCTn = 120 men
McKay et al. Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)